Literature DB >> 16456235

Peroxisome proliferator-activated receptor-gamma ligands attenuate brain natriuretic peptide production and affect remodeling in cardiac fibroblasts in reoxygenation after hypoxia.

Naoki Makino1, Masahiro Sugano, Shinji Satoh, Junichi Oyama, Toyoki Maeda.   

Abstract

Cardiac fibroblasts (CFs) participate in cardiac remodeling after hypoxic cardiac damage, and remodeling is thought to be mediated by CF synthesis of brain natriuretic peptide (BNP). It is unknown whether the peroxisome proliferator-activated receptors (PPARs), which mediate cellular signaling for growth and migration, affect BNP synthesis and whether PPARs participate in regulation of extracellular matrix protein (ECM) expression for remodeling. We examined the production of BNP in cultured neonatal ventricular CFs and its signaling system on collagen synthesis and on activation of matrix metalloproteinases (MMPs) in reoxygenation after hypoxia. BNP mRNA was detected in CFs, and a specific BNP protein, BNP1-32, was secreted into the media. Abundance of collagen I and III was increased in the media at reoxygenation. mRNA and protein levels for MMP-2 and the tissue inhibitor of metalloproteinase (TIMP)-1 were enhanced in CFs at reoxygenation. These observations also were noted in CFs after incubation with angiotensin II (10 microM) for 24 h. Pretreatment with pioglitaozone (0.1-10 microM) attenuated BNP mRNA and protein abundance of collagen III, MMP-2, and TIMP-1 in CFs at reoxygenation. The secreted BNP was also decreased by pioglitaozone in the media. Furthermore, PPAR activators inhibited reoxygenation-induced activation of nuclear factor (NF)-kappaB. These results demonstrate that PPAR activators inhibit BNP synthesis in CFs and imply that PPAR activators may regulate ECM remodeling partially through the NF-kappaB-mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456235     DOI: 10.1385/CBB:44:1:065

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  7 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.

Authors:  Bum-Yong Kang; Jennifer M Kleinhenz; Tamara C Murphy; C Michael Hart
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-16       Impact factor: 5.464

3.  Up-regulation of peroxisome proliferator-activated receptor gamma in radiation-induced heart injury in rats.

Authors:  Song Gao; Rong Wu; Yuecan Zeng
Journal:  Radiat Environ Biophys       Date:  2011-10-14       Impact factor: 1.925

4.  Naringenin interferes with the anti-diabetic actions of pioglitazone via pharmacodynamic interactions.

Authors:  Hiroki Yoshida; Rika Tsuhako; Toshiyuki Atsumi; Keiko Narumi; Wataru Watanabe; Chihiro Sugita; Masahiko Kurokawa
Journal:  J Nat Med       Date:  2016-12-03       Impact factor: 2.343

5.  Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts.

Authors:  G-H Hao; X-L Niu; D-F Gao; J Wei; N-P Wang
Journal:  Br J Pharmacol       Date:  2008-02-18       Impact factor: 8.739

6.  Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?

Authors:  David E Green; Roy L Sutliff; C Michael Hart
Journal:  Pulm Circ       Date:  2011-01-01       Impact factor: 3.017

7.  PPAR-gamma in the Cardiovascular System.

Authors:  Sheng Zhong Duan; Christine Y Ivashchenko; Michael G Usher; Richard M Mortensen
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.